Biomea Fusion develops oral drug candidates to treat diabetes and obesity. BMEA reports earnings on Tue, Nov 3, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 14 | Citizens | Target lowered | Buy | |
| Oct 14 | HC Wainwright & Co. | Reiterated | Buy | |
| Oct 7 | Brookline Capital | Initiated | Buy | |
| May 5 | Citizens | Initiated | Buy |
Seasonality
How BMEA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in BMEA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BMEA is in one of them and how their past BMEA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BMEA in an article yet. Here's the latest on the wider market.
About Biomea Fusion
Biomea Fusion is a drug developer focused on treatments for diabetes, obesity, and related metabolic diseases. Its work centers on two experimental medicines taken by mouth: icovamenib, which is being studied in type 1 and type 2 diabetes, and BMF-650, a next generation GLP-1 receptor agonist being developed for obesity. The company is based in San Carlos, California, and its target customers are patients with these conditions and the doctors who treat them. Both medicines are still in clinical development.
- Headquarters
- San Carlos, CA